Skip to main content

Table 2 Treatment response.

From: A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand

Treatment group ALN* (n = 245) MAS3** (n = 245)
Compliance, no. (%)   
Completed day 7 241 (99.6%) 240 (99.2%)
Completed day 28 232 (95.9%) 233 (96.3%)
Completed day 42 225 (93.0%) 227 (93.4%)
Cumulative proportion of patients with clinical failure, no (%)   
Day 7 0 (0) 0 (0)
Day 28 13 (5.6) 14 (6.0)
Day 42 27 (12.0) 24 (10.6)
PCR, no.   
Novel 23 14
Recrudescent 2 8
Novel + recrudescent 1 1
Indeterminate/missing 1 1
PCR-adjusted cure rates, no. (%)   
Day 7 0 (100) 0 (100)
Day 28 2 (99.1) 9(96.1)
Day 42 3 (98.8) 9 (96.3)
  1. * ALN = artemether-lumefantrine, ** MAS3 = artesunate-mefloquine
\